Persistent Asymptomatic *Plasmodium falciparum* Driven Anemia in a Treatment Re-infection Pediatric Cohort in a Rural Health District of Cameroon

Ouambo HF\(^1, 2\), Ngu LN\(^2, 3\), Lissom A\(^4\), Ngoh AA\(^4, 5\), Okoli AS\(^6\), Atabonkeng PE\(^7\), Takoua D\(^8\), Garcia R\(^9\), Gutiérrez A\(^9\), Chukwuma GO\(^10, 16\), Ngouadjue E\(^11\), Okeke MI\(^12\), Esimone CO\(^13\), Achidi EA\(^1\), Mbacham WN\(^2, 14, 15\), Kaptue L\(^16\), Park CG\(^17, 18\), Waffo AB\(^19, 20\), Assob ANC\(^1\) and Nchinda GW\(^2 *\)

\(^1\)Department of Medical Laboratory Sciences, University of Buea, Cameroon
\(^2\)Laboratory of Biochemistry, University of Yaoundé I, Cameroon
\(^3\)Department of Animal Biology and Physiology, University of Yaoundé I, Cameroon
\(^4\)Department of Biomedical Sciences, University of Dschang, Cameroon
\(^5\)Gendk, Centre for Biosafety, Tromsø, Norway
\(^6\)Department of Biochemistry, University of Dschang, Cameroon
\(^7\)Department of Medical Laboratory Sciences, University of Yaoundé I, Cameroon
\(^8\)Department of Pharmaceutical Microbiology & Biotechnology, Nnamdi Azikiwe University, Awka, Nigeria
\(^9\)Department of Medical Biology, Faculty of Health Sciences, Molecular Inflammation Research Group, UiT The Arctic University of Norway, N-9037 Tromsø, Norway
\(^10\)Department of Pharmaceutical Microbiology & Biotechnology, Nnamdi Azikiwe University, Awka, Nigeria
\(^11\)Centre de Santé Catholique de Bikop, Cameroon
\(^12\)Department of Medical Lab Sciences; Nnamdi Azikiwe University, Awka, Nigeria
\(^13\)Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Cameroon
\(^14\)Department of Medical Biology, Faculty of Health Sciences, Molecular Inflammation Research Group, UiT The Arctic University of Norway, N-9037 Tromsø, Norway
\(^15\)Department of Laboratory Medicine, University of Yaoundé I, Cameroon
\(^16\)Université des Montagnes, Bangangté, Cameroon
\(^17\)Laboratory of Immunology, Brain Korea 21 PLUS Project for Medical Science, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
\(^18\)Laboratory of Cellular Physiology and Immunology and Chris Browne Center for Immunology and Immune Diseases, Rockefeller University, New York, NY 10065, USA
\(^19\)Department of Biological Sciences/College STEM 1627 Hall Street Montgomery, AL 36101, USA
\(^20\)Center for Nano Biotechnology Research, 1627 Harris Way Montgomery, AL 36104, USA

**Abstract**

**Background:** Asymptomatic *Plasmodium falciparum* infection (APFI) resulting from partial immunity is beneficial to individuals living in malaria hyper endemic regions like Cameroon. However APFI sustains not only persistent malaria transmission in the general population but equally accounts for complications related to untreated malaria such as anemia. The aim of this study therefore was to determine the rate of anemia within a population of children with persistent APFI, living in a rural area of Cameroon.

**Materials and methods:** A cohort of children from nursery and primary school was monitored for four months in the Bikop Health District of Cameroon. Using pretested questionnaire data was collected from 80 children less than 13 years old during the months of November 2016 and February 2017. Blood samples were collected twice by venipuncture during this period. Children with acute symptoms of malaria, fever or chills and children recently sick or under malaria treatment were excluded. Using malaria rapid diagnostic kits (RDTs) and fluorescent microscopy we screened for malaria positive people and also for the hemoglobin level using a hemoglobinometer.

**Results:** The median age of participants was 6.5 (4-10). The rate of APFI increased from 41.25% in November 2016 to 65% in February 2017 irrespective of the use of Long Lasting Insecticidal Nets (LLIN). Similarity, the rate of anemia also increased (100% for the 2-5, 100% for the 6-9 years and 92.31% for the 10-13 years old children respectively). The changes in asymptomatic malaria associated anemia correlated positively (r=0.93, p=0.002) with increasing *Plasmodium falciparum* parasitemia especially with respect to moderate anemia (38.75% in the month of November and 50.00% in the month of February).

**Conclusion:** Thus asymptomatic *Plasmodium falciparum* parasitemia could be a driving force behind persistent anemia in school age children in rural areas of Cameroon.

**Keywords:** Asymptomatic malaria; Anemia; Parasitemia; Children; *Plasmodium falciparum*

**List of Abbreviation:** AL: Artemether Lumefantrine; APFI: Asymptomatic *Plasmodium falciparum* Infection; CIRCB: Centre International de Reference Chantal Biya; EDTA: Ethylene Diamine Tetra Acetate; HiCN: Hemoglobin Cyanide; HRP 2: Histidine Rich Protein; LDH: Lactate Dehydrogenase; LLIN: Long Lasting Insecticidal Net; P. falciparum: *Plasmodium falciparum*; RDT: Rapid Diagnostic Test

**Introduction**

Malaria is the deadliest disease in the human story and it still infects hundreds of millions of people every year. Despite being preventable...
and treatable, malaria is a leading cause of death and disease across many tropical and subtropical countries. In fact, in 2016, there were an estimated 216 million cases of malaria in 91 countries, with 445 000 deaths. About 90% of all malaria deaths occurred in Africa and the most afflicted were children under 5 years old [1]. Most children experience their first malaria infections during the first or second year of life, when they have not yet acquired adequate immunity, increasing their vulnerability. In addition, repeated malaria infections contribute significantly to mortality due to severe anemia, and by increasing their susceptibility to other common childhood illnesses, such as diarrhea and respiratory tract infections [2,3]. In addition to this, late presentation to the hospital, inadequate management and unavailability of effective drugs contribute significantly to the malaria morbidity and mortality [1].

Malaria is caused by the protozoan parasite Plasmodium, and six plasmodial species present a significant health threat for humans: among which P. falciparum and P. vivax the most important in terms of deaths and in a lesser extent P. ovale curtisi, P. ovale wallikeri, and P. malariae. P. knowlesi who have recently emerged as a local but important causes of the disease. Although zoontic in their aetiology, there is no definite evidence of primary human-to-human transmission yet [1,2,4]. Malaria is transmitted by the anopheles mosquitoes; in fact, the female anopheles mosquito infects the host during a blood meal by injecting the parasites into the host dermis and thereby, the life cycle progress into the human organism [5].

In Cameroon, malaria continue to be a major public health problem despite all the efforts made by the National Malaria Control Programme [6]. The estimated mortality rate of malaria is 116/1000, and it is higher than the bordering countries (104/1000) [7]. The rate of the malaria transmission depends on the region of Cameroon; in fact, except the northern regions, the transmission is perennial in most of the other regions [7]. Most data concern clinical cases, with almost 900,000 clinical cases occurring every year, whereas no data has been published on subclinical cases in Cameroon [6,7]. Indeed, APFI refers to the presence of Plasmodium falciparum in the blood without symptoms. Carriers become a reservoir for the parasite and because they do not seek treatment, they are largely responsible for persistent transmission of the disease and thereby lead to complications of malaria [3,8]. Although the suspicion of malaria has always been based on acute symptoms of the disease like fever and chills, it is currently known that these acute symptoms occur in partially immune or non-immune individuals especially children in high transmission settings and visitors to endemic areas [3]. Thus, APFI results from partial immunity which controls but does not completely eliminate the infection [3,8].

Therefore, there is a need to consider the burden of APFI in the establishment of the malaria policies, particularly in areas with high transmission rate. We carried out this study in the area of Bikop, situated in the heart of the rainforest in the Centre Region of Cameroon, an area with high malaria endemicity and perennial transmission [7]. Children living in this area are thereby highly exposed and this could enable their immune system to develop adequate immune response early in their life. However this situation could cause the appearance of APFI cases and associated anemia among the youngest children. For this purpose we ascertained the rate of asymptomatic Plasmodium falciparum infection and associated anemia within the population of children living in Bikop health area of Cameroon.

Materials and Methods

Description of the study area

This study was carried out in Bikop (3°31’00.0”N 11°25’00.0”E) [9], a health district located in the heart of the rainforest, in the Center Region of Cameroon. This is 48 Km away from Yaounde the Capital City of Cameroon. The Bikop health district covers 28 rural communities with an estimated population of 30,000 inhabitants [10]. The climate is typically equatorial with an average annual temperature of 23.5°C and mean annual rainfall of 831.7 mm [9,10]. There are two seasons; the dry season from November to February and June to August; the wet season from February to May and September to November. Agriculture and fishing are the main sources of livelihood [9,10].

Study design and ethical considerations

A cohort study was carried out for four months from November 2016 to February 2017. Ethical clearance was obtained from the Cameroon National Ethics Committee (N° 2018/01/969/CE/CNERSH/SP), Meetings were organized with the parents, the school staff and health facility staff, during which the project objectives, methods and possible benefits/risks were clearly explained. Thereafter, pupils of the nursery and primary school of Bikop were invited to participate in the survey. Assented participants were interviewed using a pretested questionnaire, to collect socio-demographic information and history of previous episodes of malaria, and treatment regiments. Parents or guardians were interviewed for participants under 5 years old. Each child received a general clinical evaluation from a clinicians of the Bikop Catholic health facility. Children with acute symptoms of malaria, fever (>37.5°C) or chills, and children recently sick [three months prior to data collection] or under antimalarial or anemia treatment were excluded from the study. All diagnosed cases of malaria and anemia were treated free of charge using artemunate-lumefantrine combination therapy for malaria, and ferrous iron-foic acid for anemia.

Samples collection and processing

During the month of November 2016, a total of 123 children were screened for the study. Temperature was recorded using an infrared body thermometer (Shenzhen calibre industries, China). During the study period 5 mL of Blood were collected using sterile disposable syringes into labelled ethylene diamine tetra acetate (EDTA) tubes, at the Bikop Catholic health facility. While the Rapid Diagnostic Test (SD Bioline Malaria Ag Pf/Pan™) for malaria and the hemoglobin concentration (hemoglobinometer Urit-12) test was immediately on site, the remaining blood were transported in an ice cooler box to CIRCB for fluorescent microscopy and sample processing for storage. Based on the selection criteria, only 80 children were finally retained in the study during the sampling period of February 2017 thereby constituting the cohort of interest in our study.

Laboratory Investigations

Malaria diagnostic

The SD Bioline Malaria Ag Pf/Pan™ (country) RDT uses Histidine-Rich Protein 2 (HRP 2) to detect P. falciparum and Lactose Dehydrogenase (LDH) for Plasmodium vivax, Plasmodium ovale and Plasmodium malariae [11-13]. This test is a WHO prequalified test useful for the region where all malaria species are circulated, and it has a sensitivity of 99.7% for P. falciparum and 95.5% for P. vivax, with a specificity of 99.3% [11,12]. The tests were used according to manufacturer’s instructions [11]. To ensure the validity of the results, RDTs were read within a timeframe of maximal 15 minutes by two independent laboratory technicians [11,12].

A fluorescent microscopy based malaria rapid diagnostic test from Partec [Partec GmbH, Germany] was also used for diagnosis of malaria.
in CIRCB. Briefly 10 µl of EDTA blood was added to ready-to-use prepared test slides incubated briefly according to the manufacturer’s instruction and read with an EVOS® cell imaging fluorescent microscope (Thermoscientific, USA) The presence of distinct bright, shiny, tiny dots observed under the UV light indicated the presence of malaria parasites [14-16]. This was counted to determine the parasitaemia for each participant.

**Hemoglobin concentration determination**

Hemoglobin concentration was determine using a portable ahemoglobinometer Urit-12 (Urit medical electronic, Jiangsu, China) a fast hemoglobin and haematocrit test providing results within 10 seconds. Briefly 10 ul of samples are dispensed into disposable microwells and read with the Urit-12. The instrument is factory precalibrated using HICN (hemoglobin cyanide) standard, and absorbance of the test solution is automatically converted to concentration of Hemoglobin. The result is displayed in less than a minute.

**Data analysis**

Data were entered using excel 2013 and analyzed with the prism statistical software. The associations between APFI and anemia were determined using Pearson’s rank correlations. Group means were compared using analysis of variance (ANOVA) and Student’s test.

**Results**

**Study population characteristics**

A total of 80 children were recruited from the 123 eligible participants screened. The eligible participants were excluded because they developed clinical malaria during the period of observation. Participants’ age ranged from 2 to 13 years old with a median age of 4 (IQR: 3-4.75). The participants were categorize into three groups according to age. This consisted of group I (2-5), group II (6-9) and group III (10-13) years old respectively. Children under five years of age (group I) were the most represented subpopulation (Table 1). The proportion of boys and girls were approximately the same with 46.25% of participants are suffering from moderate anemia independently of the age (Table 3). Most of the participating children are male with a percentage of 53.75%.

**Asymptomatic Plasmodium falciparum infection profile**

The rate of APFI increased from November 2016 to February 2017 irrespective of the age (Table 2). The increased rate was highest among children aged between 6 to 9 years (Table 2). This rate of APFI also increased within this period independently of the used of the LLIN (Table 2).

We also observed that, they was a positive correlation between the age and the increased parasitemia during the month of February ($r=0.3144$, $p=0.0045$ (Figure 1).

**Hemoglobin and anemia profiles of APFI children**

The mean level of hemoglobin decreased significantly from November 2016 to February 2017, in particular among children under five and children aged 10 to 13 years (2-5 years: 12.56 ± 2.13 to 10.72 ± 1.45; 10-13 years: 11.95 ± 1.08 to 10.31 ± 1.37. $p<0.0001$ (Table 3). Most of the participating children are suffering from moderate anemia independently of the age (Table 3).

Moreover, while the rate of APFI relapse cases increases, the rate of associated anemia also increases (Table 4).

The increased rate of APFI correlated positively with increasing anemia ($r=0.93$, $p=0.002$; (Table 5). Moreover, the increased parasitemia correlated with decreased hemoglobin level (Figure 2). This correlation significantly increased over the time (November 2016: $r=0.5615$, $p=0.0001$; February 2017: $r=0.7430$, $p=0.0001$).

**Discussion**

These studies show that a significantly high number of school children in a remote area of Cameroon were asymptomatic carriers of Plasmodium falciparum parasites. Such high rate of asymptomatic Plasmodium falciparum infection (APFI) correlated positively with an increasing anemia especially moderate anemia. APFI represents an important threat for children health in rural areas because it sustains malaria transmission year round thereby exacerbating morbidity in school age children. Nevertheless it could also be beneficial as it helps to maintain partially acquired immunity to malaria, thereby reducing the risk of severe disease [17].

The rate of APFI obtained in this study was higher with relative to the 6.8% reported in Ethiopia [18] and the 6.3% in the Lao People’s Democratic Republic [19]. This difference may be related to variations in the global malaria endemicity which is also directly linked to the transmission intensity [1,3]. For example in 2016 well over 71% of people living in Cameroon were highly exposed to malaria [20,21]. In contrast only 27% of people living in Ethiopia [20,22] and 52% of those living in the Lao People’s Democratic Republic [20,21-
We demonstrated in this study that the rate of APFI increases with age with children older than 5 being more affected than those under 5 years old [25]. Anyway, the age of onset of the acquired immunity is somewhat earlier with heavier transmission, but protection rarely occurs before the age of 2 years; the frequency of clinical disease begins to diminish and the risk of mortality sharply decreases at about 2 to 5 years of age [25]. Similarly Gupta et al. using a mathematical modeling approach showed that immunity to noncerebral severe malaria may be acquired after only one or two infections [26] but the basis of that protection and how it fails in African children each year are very poorly understood.

Malaria infected children were treated with a three day six-dose regimen of artemether-lumefantrine (AL). This is mainly because the efficacy of the six-dose regimen of AL has been confirmed globally, even in areas of widespread parasite resistance. This six-dose AL regimen is currently the approved treatment regimen for acute, uncomplicated P. falciparum malaria in adults and paediatric patients with a body weight ≥5 kg, irrespective of the immune status of the patients to P. falciparum and of the local multidrug resistance situation. This tenable in majority of countries in Africa, Asia, Europe and Latin America where the drug is registered [27,28]. To eliminate bias the drugs were administered without fatty food as recommended by the manufacturers. Nevertheless persistent detectable parasitaemia was observed four months after treatment in well over 50% of participants 2-5 years old. Detectable subclinical parasitaemia increased with age starting from 78% in
participants 6-9 years old and 93% for participants 10-13 years old. This probably indicates that the higher exposition rate leads re-infection of children, and when consider the 27-30 days needed to complete the life cycle of Plasmodium spp in human [28,29] and the half-life of the lumefantrine up to 10 days [27], it would take about two months for parasitaemia to be detected in the blood. Secondly, the persistent rate of parasitaemia could also question the efficacy of the AL combination as far as it has been demonstrated that cumulative PCR-corrected cure rates on day 28 is 100% for amodiaquine +artesunate but 97.5% for arthemether-lumefantrine [30]; Ayogu et al demonstrated that AL combination therapy reduced fever in malaria patients but failed to totally clear parasitaemia density [28]. More studies are needed to determine the impact of AL combination on the parasitaemia clearance among asymptomatic carriers of Plasmodium falciparum.

The rate of APFI in our study population increase independently of the availability of the LLIN. Less than 50% of children reported regularly using LLIN, despite their massive distribution by the Cameroon Ministry of Public Health. Although individuals who own mosquito nets must use them in order to reduce the rate of the malaria transmission between dusk and dawn, to own a LLIN do not necessary mean to use it as far as people may use it for other purposes. This is the case as reported for some villages in the North-West region of Cameroon, where 18.2% of a population used their LLINs for other purposes, such as fishing, nursing seeds and footfall nets [31]. Standing water, environmental factors including presence of grasses, outdoor activities between dusk and dawn are important risk factors for malaria transmission [32]. More efforts are therefore needed especially in these remote areas to improve the distribution of LLIN, and also to ensure the proper use of LLINs by the population in malaria hyperendemic areas.

We observed that persistent APFI correlated positively with increasing anemia, suggesting that a persistent APFI may drive anemia. In the African continent, where Plasmodium falciparum is the most prevalent human malaria parasite, anemia is responsible for about half of the malaria-related deaths [33] and specific haematological changes associated with malaria infection may vary with the level of malaria endemicity [34], malaria immunity [35] and the parasite species. Akiyana et al in 2016 demonstrated that asymptomatic malaria was associated with anemia in children of the Lao People’s Democratic Republic [19]. Anemia among children has been known as one of the major consequences of subclinical malaria and is common among children heavily exposed to the malaria parasite. In addition the greatest disease risk for these children is severe anemia rather than cerebral malaria or failure of respiratory, renal, or hepatic systems [25,26]. Central Africa, West Africa and south Asia have the lowest mean concentrations of hemoglobin and the highest prevalence of anemia in children as reported in 2011 [36]. Similarly most African countries with lowest mean concentrations of hemoglobin and the highest anemia prevalence in children have the highest rate of P. falciparum infection [36,37]. So the asymptomatic character of Plasmodium falciparum parasitaemia in children do not exclude any risk of anemia; it suggest that haemolysis of red blood cells, increased clearance of infected and uninfected cells and complement deposition on the surface of red blood cells occurs and induce anemia among APFI children [37,38]. Furthermore, while during acute malaria infection there is a rapid drop in hemoglobin, during chronic malaria infection there is a slower decline; this appear to be due to increased extravascular haemolysis of red blood cells with a concomitant failure of the bone marrow to increase red cell production to compensate for these losses [37-39].

Conclusion

Persistent APFI in a remote area of Cameroon correlated positively with moderate anemia. Thus innocuous asymptomatic Plasmodium falciparum parasitaemia might be driving force behind persistent anemia in school age children in rural forest regions of Cameroon. The findings provide a baseline for evidence-based planning and implementation of malaria control activities within these areas.

Ethics Approval and Consent to Participate

This study received ethical approval from the Cameroon National Ethics Committee for Human Health Research (Reference numbers 2015/03/561/CE/CNERSH/SP and 2018/01969/CE/CNERSH/SP) and the CIRCB institutional review board (protocol number 14-11). All participants provided written informed consent. Data were processed using specific identifiers for privacy and confidentiality purposes. Clinical data generated during the course of this study was provided free of charge to all participants.

Availability of Data and Materials

All data are fully available without restriction. Data are available from the CIRCB Institutional Data Access/Ethics Committee for researchers who meet the criteria for access to confidential data. All request for Data should be addressed to the General Manager of CIRCB reachable by the following address:

Prof. Alexis Ndjolo, Director General CIRCB, BP 3077 Messa Yaounde Cameroon, Tel. +237722315450, Fax. +237722315456, email:andjolo@yahoo.com or andjolo@circb.cm.

Competing Interests

The authors have declared that no competing interests exist.

Funding

This project was funded by grants from CIRCB, EDCTP (grant #TA.2010.40200.016) TWAS(#120599R/gbis/ac_G) and Canada grand challenge (#0121-01); to Godwin W Nhinda; from Korea-Africa cooperation (NNR-2013K1A3A1A09076155) from the National Research Foundation of Korea funded by the Ministry of Science, ICT and Future Planning in the Republic of Korea to Chae Gyu Park; and then from the Center for NanoBiologyTechnology Research (CNBR) of ASU for grant # NSF-CREST (HRD-241701) and grant # NSF-AGEP (1432991 BKR) of National Science Foundation to Alain Bopda Waffo.

Author Contributions


Acknowledgement

We thank all volunteers who consented to participate in this study. We would like to thank the personnel of the Bikop Catholic health Center and School for their help in collecting the blood samples.

References


10. cvuc.cm/national/index.php/fr/carte-communale

11. WHO Prequalification of Diagnostics Programme. PUBLIC REPORT. Product: SD Bioline Malaria Ag Pf and SD BIOLINE Malaria Ag Pf POCT. PQDx Reference Number: PQDx 0031-012-01.


15. Lifetechnologies.com/EVOS


